Semaglutide Treatment in Adult-Onset Autoimmune Diabetes: A Case Study With Long-Term Follow-Up and Periodic Evaluation of Beta-Cell Function.
| Autor: | Da Porto A; Department of Medicine, University of Udine, Udine, ITA., Varisco E; Department of Medicine, University of Udine, Udine, ITA., Antonello M; Department of Medicine, University of Udine, Udine, ITA., Casarsa V; Department of Medicine, University of Udine, Udine, ITA., Sechi LA; Department of Medicine, University of Udine, Udine, ITA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2024 Mar 08; Vol. 16 (3), pp. e55771. Date of Electronic Publication: 2024 Mar 08 (Print Publication: 2024). |
| DOI: | 10.7759/cureus.55771 |
| Abstrakt: | Latent autoimmune diabetes of adults (LADA) is a form of autoimmune diabetes that typically occurs in adulthood and has intermediate characteristics between type 1 and type 2 diabetes. To optimize the diagnostic and therapeutic approach, recently, a subclassification of LADA has been proposed based on some clinical features, antibodies, and beta cellular function at onset. In this paper, we expose an interesting case showing the effectiveness of early treatment with a glucagon-like peptide receptor agonist (semaglutide) in maintaining long-term good glycemic control and associated with the preservation of beta-cell function over a five-year observation period in a young woman with LADA. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2024, Da Porto et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|